Another Benefit of Gout Treatment: CV Risk Reduction
Growing evidence suggests that a guideline-directed, treat-to-target strategy in patients with gout not only controls the disease but also reduces cardiovascular risks.
Source: medscape.com
Stay updated with breaking news from Michael Pillinger. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Growing evidence suggests that a guideline-directed, treat-to-target strategy in patients with gout not only controls the disease but also reduces cardiovascular risks.
In countries where available, low-dose benzbromarone may warrant stronger consideration in gout with renal uric acid underexcretion, researchers say.
Learn about important updates on gout treatments, gout risk factors, gout comorbidities, and more from ACR Convergence 2021, the annual meeting of the American College of Rheumatology.